Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 19;9:12009. doi: 10.1038/s41598-019-48519-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Ephrin-A5 fails to increase Neogenin or EphA4 protein levels in growth cones of dorsal spinal cord explants. (a) Quantification of the mean Neogenin and Epha4 IF in growth cones of dorsal lumbar spinal cord explants treated with ephrin-A5 100 ng/mL for 20′ (p = 0.835 and p = 0.825 respectively). (b,c) A comparison of Neogenin and EphA4 IF levels between growth cones of LMC and dorsal spinal cord explants shows that EphA4 and Neogenin IF is greater in dorsal explants (3.1 ± 0.1-fold, p = 0.00003 and 4.11 ± 0.6-fold, p = 0.0049 respectively). Whereas ephrin-A5 increases EphA4 and Neogenin IF levels in LMC explants (2.7 ± 0.4-fold, p = 0,018; 2.6 ± 0.2-fold, p = 0,0005 respectively), EphA4 and Neogenin IF in dorsal explants remains unchanged (p = 0.734 and p = 0.949). (d,K) Examples of growth cones quantified in (b,c). Data are shown as mean ± SEM, statistical significance was tested using a two-tailed unpaired sample t-test. (a) MN media N = 6, ephrin-A5 N = 6; (b,c) MN explants/MN media N = 3, MN explants/ephrin-A5 N = 3, Dorsal explants/MN media N = 3, Dorsal explants/ephrin-A5 N = 3.